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Summary: Self-reported hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infection 
status was compared with the results of oral fluid assays of antibodies to these viruses in prisoners 
from nine of the 15 prisons in the Republic of Ireland. A total of 1205 out of 1366 prisoners 
completed a confidential questionnaire and 1193 provided analysable oral fluid specimens for 
testing for antibodies to HBV core antigen (anti-HBc), HCV (anti-HCV), and HIV (anti-HIV). The 
self-reported prevalence of hepatitis infection (hepatitis B: 5%; hepatitis C; 19%) was lower than 
that derived from oral fluid assays (anti-HBc: 9%; anti-HCV: 37%). The self-reported prevalence 
of HIV infection was similar to that found by oral fluid assay (2%). Many discrepancies were found 
between self-reported results and the results of oral fluid assays. Of those who reported being 
positive for HBV, HCV, or HIV, 4%, 5%, and 58%, respectively, tested negative on the oral fluid 
assay. Of those who reported a previous negative test result for HBV, HCV, or HIV, 10%, 37%, and 
2%, respectively, had positive oral fluid assays. Self-reports of hepatitis and HIV infection status 
are unreliable and should not be used as a basis for planning preventive and treatment services for 
prisoners. All prisoners should have the opportunity to be tested for HBV, HCV, and HIV infection. 
Commun Dis Public Health 2000; 3: 253-5. 
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 This paper describes a comparison of self-reported HBV, 
HCV, and HIV infection status with the results of oral fluid 
assays of antibodies to these viruses in the Irish prisoner 
population. 
Introduction 
Prisoners are at increased risk of infection with hepatitis B 
virus (HBV), hepatitis C virus (HCV), and HIV1-3. The most 
important risk factor is injecting drug use3-6. Prisoners’ 
knowledge of their infection status has implications for them, 
in terms of seeking and receiving treatment and prophylactic 
vaccination, and for others, in terms of preventing further 
transmission. Previous studies have shown that many of those 
infected are unaware of the fact7-9. 
Methods 
The survey was carried out between September and November 
1998 in nine of the 15 prisons in the Republic of Ireland. The 
method of selection of prisoners has been described in another 
paper5. The survey consisted of a self-completed questionnaire 
and provision of a specimen of oral fluid for testing for 
antibodies to HBV, HCV, and HIV. Participation was 
voluntary. The survey was anonymous, but individual 
questionnaires and specimens were linked. 
L Thornton 
Department of Public Health 
Eastern Regional Health Authority, Dublin 
J Barry, J Long, S Allwright, F Bradley 
 The self-reported prevalence of infection was determined 
from responses to the questions: ‘Have you ever had a blood 
test for hepatitis B? (yes/no/don’t know)’ and ‘If yes, what 
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TABLE 1 Comparison of proportions antibody positive for 
hepatitis B, hepatitis C and HIV on oral fluid test with self-
reported status: number (%) 
Status 
Oral fluid antibody 
test 
n=1193 
Self-reported status 
n=1193 
hepatitis B positive 
hepatitis C positive 
HIV positive 
104 (9) 
442 (37) 
24 (2) 
63 (5) 
229 (19) 
19 (2) 
modified Clonesystems EIA® (Biostat Diagnostics, 
Stockport). Antibodies to HBV core antigen (and-HBc) were 
tested for using Murex ICE (Abbott Diagnostics, 
Maidenhead), with positives confirmed with an ‘in-house’ 
radioimmunoassay12. Testing for HCV antibodies (anti-HCV) 
used a modified protocol for the Ortho HCV 3.0 SAVe 
ELISA® (product no. 940982, Ortho Diagnostics, 
Amersham); borderline reactives were further investigated 
using a modified Chiron RIBA® HCV 3.0 (product no. 
930780, Ortho Diagnostics, Amersham). 
 For anti-HBc, the assay sensitivity was estimated to be 
82%, and specificity to exceed 99%. For anti-HCV, the assay 
sensitivity was estimated to be 80%, and specificity 100%. For 
the anti-HIV assay, both sensitivity and specificity exceeded 
99% (manufacturer’s data). 
Results 
Eighty-eight per cent (1205) of the 1366 selected prisoners 
took part. The following analysis refers to the 1193 
participants (87%) who provided analysable oral fluid. The 
self-reported prevalence for hepatitis infection in the survey 
population was lower than that derived from the oral fluid 
assays (table 1). The self-reported prevalence of HIV infection 
was similar to that derived from the oral fluid assay. Most 
respondents reported that they had not been tested previously 
(66% (769/1170) for HBV, 63% (724/1156) for HCV, and 59% 
(699/1178) for HIV. 
 Forty-three per cent (509/1178) of the respondents 
reported ever injecting drugs. The respondents who reported 
having had previous tests differed from the overall sample in 
that they were more likely to be injecting drug users (IDUs). 
Those who reported having had a test for HCV were eight 
times more likely to be IDUs: 59% (299/505) of IDUs said 
they had had 
TABLE 2 Oral fluid antibody test results and self-reported 
infection status 
Self-reported status  
Oral fluid 
antibody test positive negative 
hepatitis B positive 
negative 
33 
30 
21 
187 
hepatitis C positive 
negative 
218 
11 
28 
47 
HIV positive 
negative 
8 
11 
8 
359 
 
 
 
 
 
 
a test compared with only 7% (45/643) of non-IDUs Those 
who reported having been tested for HBV or HIV were almost 
four times more likely to be IDUs; 50% (251/504) compared 
with 13% (83/657) for HBV and 65% (330/507) compared 
with 17% (114/661) for HIV. Consequently, the apparent 
prevalence (self-reported status) for all three infections in the 
previously tested group was considerably higher than in the 
total survey population, being 20% (63/321) for HBV, 68% 
(229/338) for HCV, and 4% (19/439) for HIV. 
 Of those who said they had been previously tested, a 
considerable number did not know the result of the testing: 
16% (50 of 321) of those tested for HBV, 10% (34 of 338) of 
those tested for HCV, and 12% (53 of 439) of those tested for 
HIV did not know the result of testing. 
 The discrepancies between self-reports and oral fluid 
assay test results, in those previously tested who knew the 
result of the testing, are given in table 2. Over a third (37%) of 
those who claimed to have had a previous negative test result 
for HCV had a positive oral fluid test result. The proportions 
who reported a negative result but whose oral fluid specimens 
were positive were lower for HBV (10%) and for HIV (2%). 
Of those who reported being HIV positive, 58% tested 
negative on the oral fluid assay. Almost a half (48%) of those 
who reported being HBV positive tested negative. Of those 
who reported that they were HCV positive, 5% were negative 
on the oral fluid test. 
Discussion 
Testing for HBV, HCV, and HIV is targeted towards IDUs, but 
the majority of prisoners, many of whom were IDUs, said they 
had not previously been tested for these three viruses. Many of 
those who had been tested did not know their results. Among 
those who reported knowledge of their results, there were 
many discrepancies between their reported results and the 
results of the oral fluid assays. 
 Possible reasons for the discrepancies include: mistakes 
in filling out the questionnaire, misunderstanding the 
questions, deliberate misrepresentation, change in antibody 
status since the previous test, and test error (including 
discrepancies between different laboratories). The non-specific 
wording of the questions asked of the prisoners may have 
resulted in ambiguous answers, particularly in relation to 
HBV. Some of those who reported a positive blood test for 
HBV but who tested negative on oral fluid may have been 
referring to a positive test for antibody to HBV surface antigen 
(anti-HBs) following earlier vaccination. An additional reason 
for the discrepancies in the hepatitis results may the low assay 
sensitivity, around 80%, for both hepatitis B and C. 
 Almost half of those who self-reported a positive result 
for HBV were antibody negative on oral fluid testing. A 
similar result was found in IDUs in England, with 38% of 
those who reported past infection being negative for anti-
HBc9. Unless previously vaccinated, these individuals remain 
susceptible to HBV but would be unlikely to avail themselves 
of, or perhaps 
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be offered, vaccination in the belief that they have already 
been infected. 
 Thirty-seven per cent of those who thought they were 
negative for HCV were antibody positive on oral fluid testing. 
As infection persists in the majority of those with HCV 
antibodies13’14, these prisoners unwittingly pose an infection 
risk to others if they engage in activities likely to transmit 
infection. Being unaware of their true infection status, they are 
also unlikely to be referred for specialist assessment and 
treatment as appropriate. 
 Eleven respondents reported they were infected with the 
HIV virus but had a negative oral fluid result. It would be of 
interest to study the psychological consequences of believing 
one is HIV positive when in fact one is negative for the 
infection. 
 The mismatch between self-reported prevalence and 
laboratory results thus has important implications for 
education and counselling programmes within the prison 
service/ and may have serious consequences for the public 
health. Prisoners who are unaware that they have been 
infected may continue to transmit infection through 
behaviours such as injecting drug use and unprotected sexual 
intercourse. Others, believing themselves already to have been 
infected when they are not, may indulge in more risky 
behaviour and as a result become infected. Knowledge of 
infection status, coupled with appropriate education and 
vaccination programmes, may result in risk behaviour 
modification and reduced risk of transmission. 
 The results of this study should be of value for those 
planning health services for prisoners. Self-reported infection 
status is unreliable and should not be used as a basis for 
planning preventive and treatment services. All prisoners 
should have the opportunity to request testing for HBV, HCV, 
and HIV directly from the prison doctor, with assurances that 
both the request and the result will be confidential. The test 
results should be provided to all those tested and the health 
professionals need to ensure that those tested understand the 
test results. Those whose tests are positive need to be advised 
about reducing the risk of transmission to others, and should 
be referred for further investigation and treatment as 
appropriate. If oral fluid rather than blood testing is used, an 
additional more sensitive test might be considered for whose 
tests for HBV and HCV are negative, as the sensitivities of the 
tests are estimated to be only 82% and 80%, respectively- All 
prisoners should be offered hepatitis B vaccination on 
committal to prison, with the exception of those with 
documented evidence of immunity. 
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